点击免费限量礼盒 摘要 ： 近日，海关总署2025年蛋白质测定仪采购项目公开招标，预算914万采购24台定氮仪。近日， 该项目中标结果公布，海能技术独揽该标，以631万元中标该项目。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 12月15日，山东省教育厅网站 公示，拟申报设置齐鲁中医药学院（生格本科、临沂工学院两 齐 鲁 中 医 药 学 院 以 山 东 中 医 药 高 等 专 科 学 校 为 建 校 基 础 ， 2023 年 纳 入 山 东 省 高 等 学 校 设 置"十四五"规划并报教育部备案，2025年12月进入山东省教育厅公示阶段（拟申报）。 作为山东省中医药领域的传统强校，学校以 中医药类专业 为核心，涵盖中医学、 中 药 学 、 针灸推拿、康复治疗学、 药学 等领域。 所高校。 若获批，将成为山东省第五所"齐鲁"系普通高校（前四所为齐鲁工业大学、齐鲁师范学院、齐 鲁理工学院、齐鲁医药学院），填补胶东半岛本科中医药教育空白。 临沂工学院 是 山东省人民政府批准建设的全日制民办非营利性普通本科学校 ，列入山东省高 校设置"十四五 ...

Core Viewpoint - GE Healthcare is committed to the Chinese market, emphasizing its strategic importance and denying rumors of selling its business in China. The company has taken concrete actions to reinforce its presence, including significant investments in local R&D and production facilities [2][3]. Group 1: Strategic Actions - GE Healthcare has established the East Hemisphere Headquarters Innovation Center for MRI in Tianjin, marking it as the only system-level MRI R&D base outside the U.S. The company plans to invest 500 million yuan over the next five years for high-end MRI equipment localization [2]. - The company has adjusted its strategy in China to focus on "precision cultivation," which includes organizational restructuring and layoffs in non-core positions, affecting less than 5% of the total workforce [2][3]. Group 2: Recruitment Strategy - GE Healthcare maintains a "reduction and increase" recruitment strategy, with approximately 150 positions open in China since 2025, primarily in R&D, production, and digitalization sectors [3]. Group 3: Localization and Production - GE Healthcare has developed the largest production base in China, with six major production sites and seven factories across various cities. The Beijing base has achieved over 50% localization for MRI core components, while the Shanghai Zhangjiang factory produces 60% of global contrast agents [5]. - The company has launched the first phase of its Precision Medicine Industrialization Base in July 2025, focusing on high-end nuclear medicine production and key component localization [5]. Group 4: R&D Focus - R&D is a core component of GE Healthcare's strategy in China, with increased investments since 2025. The Tianjin MRI Innovation Center will focus on core components and cutting-edge AI technology [6]. - The Ver sana series ultrasound devices, developed in Wuxi, feature AI-assisted diagnostic systems, achieving over 60,000 units shipped globally in the first eight months of 2025 [6]. Group 5: Market Strategy - GE Healthcare has shifted its market strategy to focus on "replacement demand" as the Chinese market transitions from new equipment installation to equipment replacement. The company offers high-end CT/MR replacement solutions emphasizing precision, lower radiation doses, and efficient workflows [7]. - The company is also targeting grassroots healthcare through products like the Ver sana series ultrasound devices and the Precision Medicine Industrialization Base, addressing the need for local healthcare solutions [7].

2025 年 12 月 17- 18 日 ， 仪 器 信 息 网 ( www. ins trument.com.cn ) 将 携 手 中 国 航 空 工 业 集 团 公 司 北 京 长 城 计 量 测 试 技 术 研 究 所 （ https : / /www.cimm.com.cn/ ） 共同举办"第四届精密测量与先进制造网络会议" 。 本届会议以"从芯到翼：精密测量的尺度革命与产业赋 能"为主题，深度聚焦 半导体、航空航天与国产精密测量仪器 三大专场，覆盖从技术前沿到产业应用的全链条视角。 主办单位： 仪器信息网 协办单位： 中国航空工业集团公司北京长城计量测试技术研究所 点击免费限量礼盒 摘要 ： 2025年12月17-18日，第四届精密测量与先进制造网络会议即将举办，国产专场专家云集，全面展现国产精密仪器的自主创新与产业赋能、国家标准解 读、技术解读等。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 参会方式： 本次会议免费参会，参会报名请扫描下方二维码或者点击 "阅读全文" ： "国产精密测量仪器与技术发展"专场预告 本专场汇聚清 ...

Core Viewpoint - The article discusses a breakthrough in rapid diagnosis of neuroendocrine tumors using a novel platform called CIOC-DCS-mini MS, which integrates carboxylate ion organic crystal functionalized paper with direct capillary spray mini mass spectrometry, enabling high-sensitivity and high-selectivity analysis without the need for chromatographic separation [1][2]. Innovation in Technology - The research team has developed a unique CIOC enrichment material that captures monoamine neurotransmitters through electrostatic and hydrogen bonding interactions, effectively removing matrix interference [3]. - An integrated "sampling-enrichment-detection" process has been created, allowing the functionalized paper strip to directly extract target substances from samples, significantly enhancing detection efficiency by eliminating complex sample preparation and chromatographic steps [3]. Performance Advantages - The platform shows significant performance improvements, with signal enhancement of 3.4 to 10.9 times in plasma and urine samples compared to unmodified paper, greatly improving the signal-to-noise ratio [4]. - Sensitivity reaches the ng level, with a linear range of 0–500 ng/mL (R² > 0.9981) and a limit of detection (LOD) as low as 0.51–2.11 ng/mL in urine samples, meeting the requirements for trace biomarker detection [5]. - The entire analysis process takes approximately 3 minutes from sample addition to mass spectrometry results, aligning with the rapid diagnostic needs of point-of-care testing (POCT) [6]. Application Prospects - The platform has been successfully used for direct detection of clinical anonymous plasma and urine samples, demonstrating its capability in real complex samples [7]. - The innovation not only miniaturizes mass spectrometry but also integrates advanced functional materials, overcoming key bottlenecks in direct analysis of complex biological samples, thus paving the way for mass spectrometry technology to transition from laboratory settings to clinical and field applications [7].

点击免费限量礼盒 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 为集中呈现2025年度"赛默飞高校分析测试优秀青年人才支撑计划"的丰富成果，促进分析测 试领域的前沿交流与跨学科融合，赛默飞世尔科技联合 中国分析测试协会高校分析测试分会 ，共同发起"赛默飞高校分析测试优秀青年人才支撑计划入选者专场直播"。本次直播特别从本 年度优秀青年人才支撑计划一、二、三类入选者中邀请四位青年学者，分享他们在不同研究层 次与方向上的创新探索，展现青年科研人才的多元视角与前沿实践。 必看的四大理由 青 年 顶 尖 力 量 云 端 集 结 ： 四 位 来 自 南 京 大 学 、 广 东 工 业 大 学 、 北 京 大 学 、 中 国 石 油 大 学 （北京）的青年科研精英，将分享涵盖材料检测、地外样品分析、免疫机制解析、环境介质表 征的前沿进展。 扫描上方二维码参与报名 跨学科创新成果深度解码 ： 从原子尺度的材料精准表征到月壤分析关键技术，从质谱多组学 新技术到大规模环境分子数据库构建，全面呈现分析测试技术的前沿应用与跨越式发展。 重磅嘉宾与报告前瞻 孙敬 ...

Core Insights - The digital PCR market in China is experiencing intense competition, with three leading brands: Bio-Rad, QIAGEN, and Xinyi, following Bio-Rad's acquisition of Stilla, which significantly increased its market share in the research sector [1][2]. Market Overview - The digital PCR market is characterized by a diverse landscape, with domestic brands accounting for a significant portion of the market share in terms of units sold, while imported brands maintain a revenue advantage due to higher pricing [3][5]. - In terms of bid amounts, imported brands hold a 48.91% share, while domestic brands account for 40.45%, with the remainder attributed to unknown brands [5]. - Domestic brands have captured 50% of the total units sold, indicating a trend towards "domestic substitution," driven by cost-effectiveness and localized service advantages [7]. Procurement Analysis - The primary demand for digital PCR technology comes from academic institutions and hospitals, which are the core procurement entities [8]. - The top three procurement entities by bid amount are universities (35.97%), hospitals (27.66%), and research institutes (13.18%), collectively representing over 74% of the market [10][12]. Brand Competition - Bio-Rad leads the market with a bid amount share of 24.51%, followed by QIAGEN at 19.91% and Xinyi at 16.74% [14]. - In terms of units sold, Xinyi leads with a 19.23% share, followed by Bio-Rad at 16.35% and QIAGEN at 15.38% [17]. - The acquisition of Stilla by Bio-Rad is expected to further enhance its market position, potentially increasing its unit bid share to 20.19% and bid amount share to 28.24% [17]. Research Market Dynamics - The research sector, encompassing universities and research institutes, is the largest application market for digital PCR, with Bio-Rad, QIAGEN, and Xinyi occupying the top three positions in bid amounts [21]. - In the research market, Bio-Rad holds a bid amount share of 29.43%, QIAGEN at 21.10%, and Xinyi at 15.85%, indicating strong brand loyalty and performance [21]. - After including Stilla's data, Bio-Rad's bid amount share in the research sector could rise to 33.92%, further solidifying its leadership [23]. Summary and Outlook - The digital PCR market from January to October 2025 illustrates a landscape of "imported leadership, domestic rise, and diversified competition," with Bio-Rad maintaining its leadership in high-end research markets [24]. - Domestic brands are becoming mainstream due to competitive pricing strategies, and the market is expected to expand further with advancements in molecular diagnostics and increased funding for research [24].

点击免费限量礼盒 摘要 ： 近日，海关总署2025年蛋白质测定仪采购项目公开招标，预算914万采购24台定氮仪。近日，该项目中标结果公布，海能技术独揽该标，以631万元中 标该项目。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 以下为中标详情： 一、项目编号： CG2025-PL-GK-HW-055 二、项目名称： 海关总署2025年蛋白质测定仪采购项目 三、中标信息 包件1 供应商名称：湖北科纳汇科技有限公司 供应商地址：洪山区文治街32号武昌府二期西区5号商业B座19层13室 日前，海关总署2025年蛋白质测定仪采购项目公开招标，预算914万采购24台定氮仪。 近日，该项目中标结果公布， 海能技术 独揽该标， 以 631 万元中标该项目。 中标金额：5,592,940.00元 评审总得分：87.60分 四、主要标的信息： | | | 货物采购信息表 | | | | | --- | --- | --- | --- | --- | --- | | | | 货 | | | 货物单 | | 供应商 | 货物 | 物 | 货物型号 | 货物数 ...

Core Insights - The General Administration of Customs has announced the procurement of 78 gas chromatographs for 2025, with a total value of 22.8788 million yuan [1][2] - Agilent has won the bid for 57 units of the 8890 model, amounting to 16.88 million yuan, while Fuli has secured 21 units of the F80 model for 5.9988 million yuan [1][2] Procurement Details - Total procurement includes 78 gas chromatographs with a total budget of 22.8788 million yuan [1][2] - Breakdown of winning bids: - Agilent 8890: 57 units, 16.88 million yuan - Fuli F80: 21 units, 5.9988 million yuan [1][2] Equipment Specifications - Various models and pricing details of gas chromatographs are provided, including: - GC-ECD: 3 units at 213,000 yuan each - GC-FID: 1 unit at 248,500 yuan - GC-FID-ECD: 12 units at 324,000 yuan each - Fuli F80: 10 units at 275,400 yuan each [3]

点击免费限量礼盒 摘要 ： 2025年12月14日，苏州博众仪器自主研发的200kV热场发射透射电镜BZ-F200下线发货，打破 海外垄断，标志我国透射电镜迈入自主化商用阶段。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 2025年12月14日，苏州博众仪器科技有限公司（以下简称"博众仪器"） 自主研发的200kV 热场发射透射电镜——BZ-F200正式下线发货 ，标志着我国在透射电镜领域彻底打破海外垄 断，迈入自主化商用的全新阶段。 作 为 国 产 高 端 透 射 电 镜 领 域 的 突 破 之 作 ， BZ-F200 具 备 国 际 先 进 性 能 ， 其 点 分 辨 率 达 0.25nm，晶格分辨率达0.10nm，可广泛应用于半导体、材料科学、生命科学等关键领域。 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号 立 场 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 来 源 ： 仪 器 信 息 网 | 作 者 ...

Core Insights - Linyi University has announced procurement intentions for 22 items of laboratory equipment, with a total budget of 103 million yuan, expected to be procured between February and December 2025 [1][2]. Procurement Overview - The procurement includes various advanced instruments such as: - Liquid Chromatography-Mass Spectrometry (LC-MS) systems - Ultra-High-Performance Liquid Chromatography (UHPLC) - Gel Permeation Chromatography (GPC) - Gas Chromatography (GC) and Gas Chromatography-Mass Spectrometry (GC-MS) [1][2]. - Specific budget allocations for key items include: - Two-Photon Laser Scanning Confocal Microscope: 6.6 million yuan - Small Animal Single Photon Emission Computed Tomography (SPECT): 3.5 million yuan - Small Animal 3D Photoacoustic Imaging System: 4.8 million yuan - Brain Magnetic Resonance Imaging System: 8.99 million yuan - Microfluidic Medical Dual-Sided Photolithography Machine: 5.37 million yuan - High-Throughput Automated Membrane Clamp: 5.37 million yuan - Various chromatography systems: 9.59 million yuan [2][4]. Equipment Categories - The procurement covers a wide range of categories, including: - Biological and medical engineering equipment - Imaging systems - Chromatography instruments - Microscopes and flow cytometers - Material testing devices [2][4][6]. - Total budget for specific categories includes: - Biological and medical analysis equipment: 10.48 million yuan - Material characterization devices: 10.8 million yuan - Flow cytometry instruments: 6.2 million yuan [4].